Page last updated: 2024-10-31

molsidomine and Idiopathic Parkinson Disease

molsidomine has been researched along with Idiopathic Parkinson Disease in 8 studies

Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.

Research Excerpts

ExcerptRelevanceReference
"We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)."7.73Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006)
"We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)."3.73Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's5 (62.50)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Solís, O1
Espadas, I1
Del-Bel, EA1
Moratalla, R1
Di Matteo, V1
Pierucci, M1
Benigno, A1
Crescimanno, G1
Esposito, E1
Di Giovanni, G1
Hung, LW1
Villemagne, VL1
Cheng, L1
Sherratt, NA1
Ayton, S1
White, AR1
Crouch, PJ1
Lim, S1
Leong, SL1
Wilkins, S1
George, J1
Roberts, BR1
Pham, CL1
Liu, X1
Chiu, FC1
Shackleford, DM1
Powell, AK1
Masters, CL1
Bush, AI1
O'Keefe, G1
Culvenor, JG1
Cappai, R1
Cherny, RA1
Donnelly, PS1
Hill, AF1
Finkelstein, DI1
Barnham, KJ1
Lev, N1
Melamed, E1
Offen, D1
Jiang, H1
Wu, YC1
Nakamura, M1
Liang, Y1
Tanaka, Y1
Holmes, S1
Dawson, VL1
Dawson, TM1
Ross, CA1
Smith, WW1
Ebadi, M1
Sharma, S1
Krzaścik, P1
Kostowski, W1
Naoi, M1
Maruyama, W1

Other Studies

8 other studies available for molsidomine and Idiopathic Parkinson Disease

ArticleYear
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
    Neurobiology of disease, 2015, Volume: 73

    Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dop

2015
Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study .
    Annals of the New York Academy of Sciences, 2009, Volume: 1155

    Topics: Animals; Corpus Striatum; Indazoles; Male; Molsidomine; Nitric Oxide; Nitric Oxide Donors; Oxidopami

2009
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.
    The Journal of experimental medicine, 2012, Apr-09, Volume: 209, Issue:4

    Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Cognition; Coordination Complexes; Disease Models, Anima

2012
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
    Neuroscience letters, 2006, May-15, Volume: 399, Issue:1-2

    Topics: alpha-Synuclein; Benzothiazoles; Cell Differentiation; Cell Line, Tumor; Cytoplasm; Ferrous Compound

2006
Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Neurobiology of aging, 2007, Volume: 28, Issue:11

    Topics: alpha-Synuclein; Animals; Cell Death; Dose-Response Relationship, Drug; Genetic Predisposition to Di

2007
Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease.
    Experimental biology and medicine (Maywood, N.J.), 2006, Volume: 231, Issue:9

    Topics: Animals; Apoptosis; Caspase 3; Caspases; Coenzymes; Dopamine; Enzyme Activation; Lipid Peroxidation;

2006
Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
    Polish journal of pharmacology, 1997, Volume: 49, Issue:4

    Topics: Animals; Arginine; Catalepsy; Disease Models, Animal; Haloperidol; Male; Molsidomine; Nitric Oxide S

1997
Future of neuroprotection in Parkinson's disease.
    Parkinsonism & related disorders, 2001, Volume: 8, Issue:2

    Topics: Apoptosis; Humans; Molsidomine; Neuroprotective Agents; Neurotoxins; Nitric Oxide Donors; Oxidopamin

2001